Abstract:Introduction: Understanding the differences between respiratory syncytial virus (RSV) subgroups A and B provides insights for the development of prevention strategies and public health interventions. We aimed to describe the structural differences of RSV subgroups, their epidemiology, and genomic diversity. The associated immune response and differences in clinical severity were also investigated. Methods: A literature review from PubMed and Google Scholar (1985-2023) was performed and extended using snowballing from references in captured publications. Results: RSV has two major antigenic subgroups, A and B, defined by the G glycoprotein. The RSV F fusion glycoprotein in the prefusion conformation is a major target of virus neutralizing antibodies and differs in surface exposed regions between RSV A and RSV B. The subgroups co-circulate annually, but there is considerable debate as to whether clinical severity is impacted by the subgroup of the infecting RSV strain. Large variations between the studies reporting RSV subgroup impact on clinical severity were observed. A tendency for higher disease severity may be attributed to RSV A but no consensus could be reached as to whether infection by one of the subgroup caused more severe outcomes. RSV genotype diversity decreased over the last two decades, and ON and BA have become the sole lineages detected for RSV A and RSV B, since 2014. No studies with data obtained after 2014 reported a difference in disease severity between the two subgroups. RSV F is relatively well conserved and highly similar between RSV A and B, but changes in the amino acid sequence have been observed. Some of these changes led to differences in F antigenic sites compared to reference F sequences (e.g., RSV/A Long strain), which are more pronounced in antigenic sites of the prefusion conformation of RSV B. Initial results from the second season after vaccination suggest specific RSV B efficacy wanes more rapidly than RSV A for RSV PreF-based monovalent vaccines. Conclusions: RSV A and RSV B both contribute substantially to the global RSV burden. Both RSV subgroups cause severe disease and none of the available evidence to date suggests any differences in clinical severity between the subgroups. Therefore, it is important to implement measures effective at preventing disease due to both RSV A and RSV B to ensure impactful public health interventions. Monitoring overtime will be needed to assess the impact of waning antibody levels on subgroup-specific efficacy.

Clinical and biological consequences of respiratory syncytial virus genetic diversity

The Comparative Genomics of Human Respiratory Syncytial Virus Subgroups A and B: Genetic Variability and Molecular Evolutionary Dynamics

Genetic diversity and molecular evolution of human respiratory syncytial virus A and B

Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies

Revisiting respiratory syncytial virus’s interaction with host immunity, towards novel therapeutics

Genomic Evolution and Surveillance of Respiratory Syncytial Virus during the 2023–2024 Season

Microbiological and epidemiological features of respiratory syncytial virus

Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic

Evolutionary trends of respiratory syncytial viruses: Insights from large-scale surveillance and molecular dynamics of G glycoprotein

Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures

Respiratory Syncytial Virus

The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

RSV genomic diversity and the development of a globally effective RSV intervention

Host Components Contributing to Respiratory Syncytial Virus Pathogenesis

Genomic characterization of respiratory syncytial virus genotypes circulating in the paediatric population of Sydney, NSW, Australia

Association of disease severity and genetic variation during primary Respiratory Syncytial Virus infections

Transmission patterns and evolution of respiratory syncytial virus in a community outbreak identified by genomic analysis

Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus

Respiratory syncytial virus infection and novel interventions

Phylogeny and population dynamics of respiratory syncytial virus (Rsv) A and B